| Exact Sciences is a cancer diagnostics company. Co. has developed several brands in cancer screening and diagnostics, including Cologuard and Oncotype DX. Co. has developed a non-invasive screening test called Cologuard® to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co. is also working on the development of additional tests for other types of cancer. Co. is also focusing its research and development efforts on building a pipeline of potential future products and services with a focus on blood-based tests. Co. is advancing liquid biopsy through biomarker discovery and validation in tissue, blood and other fluids. We show 47 historical shares outstanding datapoints in our coverage of EXAS's shares outstanding history.|
Understanding the changing numbers of EXAS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like EXAS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching EXAS by allowing them to research EXAS shares outstanding history
as well as any other stock in our coverage universe.